1. Cost-effectiveness of a cardiovascular polypill strategy (aspirin, atorvastatin, ramipril) for the secondary prevention of cardiovascular disease based on real life improvement in risk factor control. (11th May 2021) Authors: Rubio, G; Araujo, F; Aguiar, C; Carcedo, D; Abreu-Oliveira, TP; Paz, S; Castellano, JM Journal: European journal of preventive cardiology Issue: Volume 28:Supplement 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cost-effectiveness of the CNIC-polypill strategy for the secondary prevention of CV disease in male and female patients with established coronary heart disease based on improved risk factor control. (14th October 2021) Authors: Aguiar, C; Araujo, F; Rubio, G; Carcedo, D; Abreu-Oliveira, T P; Paz, S; Castellano, J M; Fuster, V Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. How consistent are cost-effectiveness estimates of a cardiovascular polypill strategy for the secondary prevention of cardiovascular disease across different cardiovascular risk equations?. (11th May 2021) Authors: Rubio, G; Aguiar, C; Araujo, F; Carcedo, D; Abreu-Oliveira, TP; Paz, S; Castellano, JM Journal: European journal of preventive cardiology Issue: Volume 28:Supplement 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗